Changes in expression of IL-17, RORγt, foxP3 mRNA levels in tumours were documented by qRT-PCR. Results: We found that HE staining of tumor specimens show a number of cancer cells with hyperchromatic nuclei and mitotic figures. The average volume of tumours in group (0.291 cm3) with HP-NAP-treated was smaller than gastric cancer group (0.409 cm3), and there was a mouse with peritoneal metastasis and hemorrhagic ascites in latter group. Expression of VEGF mRNA was significantly lower in intervetion group than gastric cancer group (P = 0.004). In addition, number of Th17

and Treg cells in gastric carcinoma group was significantly higher than the normal group (P = 0.013, P = 0.022). Th17 cells of intervention group was obviously higher than that of gastric cancer group (P = 0.026). However Treg cells in the spleen had no significant difference between intervention buy BGB324 group and gastric cancer group (P > 0.05). The expression of IL-17,RORγt mRNA in intervention group was obviously higher than gastric carcinoma group B-Raf mutation (P = 0.033, P = 0.002),

while expression of foxP3 mRNA has no obvious difference (P = 0.059). Conclusion: Our findings indicate that HP-NAP increase peripheral Th17 cells and the infiltrating of IL-17 in tumor microenvironment to inhibit the development of gastric cancer directly or indirectly. Key Word(s): 1. HP-NAP; 2. Gastric carcinoma; 3. Th17/Treg cells; 4. VEGF; Presenting Author: SAHNGWEI JI Additional Authors: YONGGUI ZHANG, JIANGBIN WANG Corresponding Author: SAHNGWEI JI Affiliations: China-Japan Union Hospital of Jilin University Objective: To investigate the seroprevalence of H.pylori infection in patients with the chronic hepatitis B and the synergistic effect with HBV on the development of the chronic hepatitis B. Methods: In this case-control

study, the cases were 853 patients with the chronic hepatitis B (607 males, 196 females, mean age 35.3 ± 15.7 years). The controls were 729 sex and age matched healthy donors (515 males, 214 females, mean age 36.6 ± 14.5 years). All subjects were tested for presence in serum of IgG antibodies against H.pylori, and the cases were tested the quantitation and genotypes of HBV selleck products DNA. The result was analyzed using the chi-square test. Results: H.pylori infection was more prevalent in patients with the the chronic hepatitis B (59.6%), the chronic HBV-related cirrhosis (77.3%), and the HCC (80.3%) than in healthy controls (43.3%)(p < 0.05). Moreover, the seroprevalence of H.pylori in patients with the chronic cirrhosis and the HCC was higher than that in patients with the chronic hepatitis (p < 0.05). With the different virus load of HBV DNA, H pylori prevalence all increased, but there was no significant difference among the groups of the different virus loads. H.pylori prevalence in patients with genotyping A, B, C and D was 40.0%, 50.9%, 50.9% and 52.6%, respectively.